X0306 4 2018-07-31 1 0001488613 Foundation Medicine, Inc. FMI 0001585017 Ryan Jason 150 SECOND STREET C/O FOUNDATION MEDICINE, INC. CAMBRIDGE MA 02141 0 1 0 0 Chief Financial Officer Common Stock 2018-07-31 4 U 0 6955 137.00 D 42215 D Common Stock 2018-07-31 4 J 0 42215 137.00 D 0 D stock option (right to buy) 7.12 2018-07-31 4 H 0 1562 0.00 D 2023-05-21 Common Stock 1562 0 D Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. /s/ Robert W. Hesslein, as Attorney-in-Fact for Jason Ryan 2018-08-02